Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference

SHANGHAI, China and CUPERTINO, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that executive management will participate in the Cantor Fitzgerald Global Healthcare Conference to be held September 25-27, 2017 at the InterContinental New York Barclay Hotel. Tony (Bizuo) Liu, Chief Executive Officer of CBMG, will provide an overview of the Company on Wednesday September 27, 2017, which will also be available for viewing as a live webcast.

Conference: Cantor Fitzgerald Global Healthcare Conference
Date:  Wednesday September 27, 2017
Time:  10:55 – 11:25 AM EDT
Title:  CBMG, a Leading Biomedicine Innovator for Cancers & Degenerative Diseases
Location:  Grand Ballroom 2, InterContinental New York Barclay Hotel, 111 E 48th Street, NY
Live webcast:  http://www.cellbiomedgroup.com/investor-relations/presentations/ 

About Cellular Biomedicine Group 
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat Refractory Diffuse Large B-cell Lymphoma (DLBCL), a Phase I human clinical trial to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL), as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. The Company also recently announced a strategic partnership with GE Healthcare Life Sciences China to establish a joint technology laboratory to develop control processes for the manufacture of CAR-T and stem cell therapies. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Contact:
Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

Ads

You May Also Like

Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update

Announces Appointments of Michael Pehl as President and Chief Executive Officer and Brendan Delaney ...

Summit Therapeutics to Participate in Upcoming Investor Conferences

Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR ...